cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies.
However, the efficacy of targeted therapies has challenged this standard. We assessed the
role of nephrectomy in patients with metastatic renal-cell carcinoma who were receiving
targeted therapies. Methods In this phase 3 trial, we randomly assigned, in a 1: 1 ratio,
patients with confirmed metastatic clear-cell renal-cell carcinoma at presentation who were …